NVision

NVision is a German deep-tech company founded in 2015 and headquartered in Ulm. Its near-term commercial platform, POLARIS, uses engineered organic precursors and parahydrogen-induced polarization (PHIP) to amplify the MRI signal of metabolic tracers such as pyruvate. The company’s stated value proposition is practical metabolic imaging on standard MRI systems, with polarization performed without the cryogenic, long-duration workflow associated with dissolution dynamic nuclear polarization. That can make biological response visible on a much shorter timescale than conventional morphology-based imaging, particularly for oncology research, treatment monitoring, and translational drug-development studies. POLARIS is therefore a quantum-enabled imaging workflow rather than a general-purpose MRI replacement: its adoption depends on reproducible chemistry, tracer handling, clinical protocols, and evidence that the additional metabolic signal changes decisions or trial economics.

The company is now extending the same molecular spin-control expertise into quantum computing through PIQC (Photonic Integrated Quantum Circuits). NVision describes PIQC as a molecular quantum-node approach in which engineered carbene molecules combine an optically active electron spin, a longer-lived nuclear-spin memory, and single-photon emission. The proposed architecture deposits thin organic films onto photonic chips so that the quantum material has a native optical interface and can use established photonic-integration processes. NVision reports more than 2 milliseconds of coherence in its 2026 single-molecule demonstration and operation at approximately 2–4 K, but those results should be read as component and architecture evidence, not proof of a fault-tolerant commercial machine. The key technical diligence questions are repeatability across devices, optical coupling and yield, gate fidelity, error-correction overhead, packaging, and whether the chemistry remains stable through fabrication and operation.

Commercial traction is more credible on the sensing side than on the computing side. NVision states that POLARIS systems are being installed at leading cancer centers and are expected to reach approximately 20 centers across the United States, Europe, and Asia by the end of 2026; the company names Memorial Sloan Kettering, the University of Cambridge, and Technical University of Munich among sites or collaborators. These are useful deployment signals, but they do not by themselves establish recurring revenue, regulatory clearance, clinical utility, or reimbursement. In May 2026 NVision announced a $55 million Series B anchored by Abbott, including a $17 million EIB venture loan, bringing stated total capital raised to $120 million. The financing and Abbott’s strategic participation improve validation and distribution potential, while also raising the diligence bar around productization, quality systems, and the boundary between research collaboration and paid clinical deployment.

Competitive dynamics differ across the two programs. POLARIS competes with established hyperpolarized-MRI approaches such as dissolution DNP, other PHIP and metabolic-imaging platforms, and conventional MRI plus contrast-agent workflows. PIQC competes for technical attention and capital with superconducting, trapped-ion, neutral-atom, silicon-spin, diamond-spin, and photonic quantum-computing architectures. NVision’s differentiator is the attempt to reuse molecular design and spin-control capabilities across a deployed sensing product and a longer-horizon compute platform. That shared foundation could create defensible know-how in molecular synthesis, spin chemistry, and integration; it could also split management attention and capital before either business reaches scale. DLR’s COMIQC project provides meaningful public evidence of government-supported prototype work, including a target of at least 50 molecular spin qubits, but it remains a development program rather than an operational defense or sovereign-compute deployment.

NVision has credible dual-use potential, but no public evidence in the reviewed sources establishes a defense customer, classified program, or fielded security application. POLARIS is principally a healthcare and life-sciences product. PIQC and the underlying molecular-spin, photonic-interface, and quantum-control capabilities could eventually matter to allied quantum-computing capacity, secure scientific computing, sensing, and technology sovereignty; these are strategic-enabling adjacencies, not demonstrated defense revenue. The record should therefore treat strategic relevance as contingent on technical scaling, export-control compliance, cybersecurity, supply-chain resilience, and mission-relevant benchmarks. The main diligence path is to verify independent performance data, clinical and regulatory milestones, deployment economics, financing runway, fabrication partners, intellectual-property freedom to operate, and whether the company can maintain healthcare execution while building a second quantum-computing platform.